Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection.

Literature DB >> 11854261

A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection.

Helen C Flick-Smith¹, Nicola J Walker, Paula Gibson, Helen Bullifent, Sarah Hayward, Julie Miller, Richard W Titball, E Diane Williamson.

Abstract

The immunogenicity and protective efficacy of overlapping regions of the protective antigen (PA) polypeptide, cloned and expressed as glutathione S-transferase fusion proteins, have been assessed. Results show that protection can be attributed to individual domains and imply that it is domain 4 which contains the dominant protective epitopes of PA.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2002 PMID： 11854261 PMCID： PMC127760 DOI： 10.1128/IAI.70.3.1653-1656.2002

Source DB: PubMed Journal: Infect Immun ISSN： 0019-9567 Impact factor: 3.441

18 in total

1. Involvement of domain 3 in oligomerization by the protective antigen moiety of anthrax toxin.

Authors: J Mogridge; M Mourez; R J Collier
Journal: J Bacteriol Date: 2001-03 Impact factor: 3.490

2. Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig.

Authors: S F Little; G B Knudson
Journal: Infect Immun Date: 1986-05 Impact factor: 3.441

3. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity.

Authors: P C Turnbull; M G Broster; J A Carman; R J Manchee; J Melling
Journal: Infect Immun Date: 1986-05 Impact factor: 3.441

4. Role of toxin functional domains in anthrax pathogenesis.

Authors: F Brossier; M Weber-Levy; M Mock; J C Sirard
Journal: Infect Immun Date: 2000-04 Impact factor: 3.441

5. Presentation of protective antigen to the mouse immune system: immune sequelae.

Authors: E D Williamson; R J Beedham; A M Bennett; S D Perkins; J Miller; L W Baillie
Journal: J Appl Microbiol Date: 1999-08 Impact factor: 3.772

6. Immunoelectrophoretic analysis, toxicity, and kinetics of in vitro production of the protective antigen and lethal factor components of Bacillus anthracis toxin.

Authors: J W Ezzell; B E Ivins; S H Leppla
Journal: Infect Immun Date: 1984-09 Impact factor: 3.441

Review 7. Anthrax vaccines: past, present and future.

Authors: P C Turnbull
Journal: Vaccine Date: 1991-08 Impact factor: 3.641

8. Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin.

Authors: K R Klimpel; S S Molloy; G Thomas; S H Leppla
Journal: Proc Natl Acad Sci U S A Date: 1992-11-01 Impact factor: 11.205

9. Anthrax protective antigen interacts with a specific receptor on the surface of CHO-K1 cells.

Authors: V Escuyer; R J Collier
Journal: Infect Immun Date: 1991-10 Impact factor: 3.441

10. Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process.

Authors: A M Friedlander
Journal: J Biol Chem Date: 1986-06-05 Impact factor: 5.157

41 in total

1. Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge.

Authors: Sherry R Crowe; Linda L Ash; Renata J M Engler; Jimmy D Ballard; John B Harley; A Darise Farris; Judith A James
Journal: J Infect Dis Date: 2010-07-15 Impact factor: 5.226

2. Protection against anthrax toxemia by hexa-D-arginine in vitro and in vivo.

Authors: Miroslav S Sarac; Juan R Peinado; Stephen H Leppla; Iris Lindberg
Journal: Infect Immun Date: 2004-01 Impact factor: 3.441

Review 3. Development of an improved vaccine for anthrax.

Authors: Stephen H Leppla; John B Robbins; Rachel Schneerson; Joseph Shiloach
Journal: J Clin Invest Date: 2002-07 Impact factor: 14.808

4. Analysis of antibody responses to protective antigen-based anthrax vaccines through use of competitive assays.

Authors: Rebecca A Brady; Anita Verma; Bruce D Meade; Drusilla L Burns
Journal: Clin Vaccine Immunol Date: 2010-07-14

Review 5. Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.

Authors: S Ramasamy; C Q Liu; H Tran; A Gubala; P Gauci; J McAllister; T Vo
Journal: Br J Pharmacol Date: 2010-10 Impact factor: 8.739

6. Induction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: implications for disparate immune system priming pathways.

Authors: William A Langley; Konrad C Bradley; Zhu-Nan Li; Mary Ellen Smith; Matthias J Schnell; David A Steinhauer
Journal: J Virol Date: 2010-05-26 Impact factor: 5.103

10. Cloning, expression and purification of binding domains of lethal factor and protective antigen of Bacillus anthracis in Escherichia coli and evaluation of their related murine antibody.

Authors: Mehdi Rezaee; Hossein Honari; Mohammad Reza Ashrafi Kooshk
Journal: Mol Biol Rep Date: 2014-01-16 Impact factor: 2.316